The FDA accepted Nanoscope's BLA for MOGENRY (sonpiretigene isteparvovec, MC-010), a gene therapy for retinitis pigmentosa with severe vision loss, supported by RESTORE trial data showing sustained BCVA improvement.
News
Advertisement
Piotr A. Woźniak, MD, PhD, previews the ESCRS' growing focus on AI-assisted digital surgery and an expanding dry eye programme.
Advertisement
Ahead of the 44th ESCRS Congress in London, a look at the presbyopia-correcting IOL, glaucoma and dry eye disease research on this year's scientific programme.
Dante Pieramici, MD, discusses the phase 3 COMO and CAPRI trials of EYP-1901 in diabetic macular edema and what 6-month dosing could mean for treatment burden.
Andrew G. Lee, MD, and Drew Carey, MD, break down a debate over PDE-5 inhibitor use after non-arteritic anterior ischemic optic neuropathy.
New research covers a 3D OCT foundation model, an OCTA biomarker review and offline smartphone screening for three retinal diseases.
Advertisement
Startup S5G Therapeutics aims to move ubiquinol technology from the laboratory toward treatments for dry eye, Fuchs dystrophy, and other corneal conditions.
A VR lens simulator used at InVision Eye Care lifted premium IOL conversion rates from 30%-35% to the mid-40s
Study authors discuss fishing-related eye injury patterns, pediatric risk, and prevention strategies drawn from other sports.
A gamified program may speed the brain’s adjustment, new data suggest.
Advertisement
Women's Health: Giant cell arteritis and the sex gap: what every eye care clinician should know
Published: | Updated:
Giant cell arteritis, long known by its more familiar name, temporal arteritis, is the most common vasculitis in adults over 50 and a true ophthalmic emergency. If untreated, it can result in permanent bilateral vision loss within days. Women are more often afffected than men, the the disease manifests differently between the sexes.
Ashraf Ahmad, MD, explains what tear breakup time testing shows and why results vary between clinic visits.
Scaling telemedicine-based screening for retinopathy of prematurity in sub-Saharan Africa
ByArthur R. Brant, MD,Sarthak V. Shah, MD,Akwasi Ahmed, MD, MBA,Imoro Braimah, MD,Naana Wireko Brobby, MD,Kwabena Onwona-Agyeman, MD,Dominic Masonuo Bagbio, MD,Gilbert Bonsaana, MD,Samuel Bondzie, MD,Jacquelyn Adu, MD,Muniratu Alhassan, BS,Sadik T. Sherief, MD,Asrat Demptse, MD,Eyerusalem Haregewoyn, MD,Celina Mhina, MD,Martha Mkony, MD,Ahmad Al-Moujahed, MD, PhD,Ahmad Kunbaz, MD,Celine Chaaya, MD, MSc,Cindy S. Zhao, MD, MBA,Geoffrey C. Tabin, MD,Nimesh A. Patel, MD,Darius M. Moshfeghi, MD
Zero Blind Babies uses wide-field retinal imaging and telemedicine to expand ROP screening across Ghana, Ethiopia, Tanzania, and Syria—screening 400 infants weekly at $56 per QALY—while stressing that local staff and complete-pathway systems remain essential.
Ocugen's global phase 3 ArMaDa3 trial evaluates OCU410, a one-time gene therapy targeting multiple disease pathways in geographic atrophy secondary to dry age-related macular degeneration.
Thyroid Eye Disease (TED) is an autoimmune condition affecting around one in 1,000 people in Europe. Its variability of symptoms and close association with Graves' disease, a separate thyroid disorder, can lead to considerable challenges in diagnosis. Earlier detection depends on strong collaboration between endocrinologists and ophthalmologists, as well as conversations that fully explore the impact of symptoms on patients' daily lives.
Dante Pieramici, MD, on how a sustained-release TKI dosed every six months could cut clinic volume, ease treatment burden, and protect patients who otherwise disappear from care.
Jay Chhablani, MD, on how MacTel eyes turn neovascular, when to refer, and what Encelto means for treatment.
Cataract safety, Glaucoma drugs and MIGS, plus Artificial Intelligence debates and retina breakthroughs—key FDA moves and trial updates in ophthalmology.
Jordi Mones, MD, PhD, discusses what is believed to be the first direct-to-phase 2 trial testing an optogenetic gene therapy to restore vision lost to GA.
A same-platform, prospective comparison of 123 eyes suggests diffractive trifocal optics don't compromise standard automated perimetry outside the central 5°
Survey reveals most women don't recognize dry eye as a symptom of perimenopause or menopause.
Retina specialist David A. Eichenbaum, MD, FASRS, discusses KSI-101 (tabirafusp alfa), a dual IL-6/VEGF-blocking biologic in the Phase 3 PEAK trial, as a potential steroid-sparing, first-line therapy for uveitic macular edema.
Yehia Hashad, MD, discusses BL1332's phase 1b pain data and what's ahead as the TRPV1 antagonist enters phase 2 in patients with PRK.
Cerebral visual impairment is now the leading cause of childhood vision loss. Three experts explain the history, science, and clinical signs eye care providers need to know.
Esen Akpek, MD, weighs in on lifitegrast-perfluorohexyloctane phase 2 data and what it means for the drop's path to phase 3.
A priority review in Stargardt disease, two pivotal-trial milestones, an emerging bispecific for wet AMD, and new diagnostic guidance defined a busy August for retina.
Antibiotic injection reduced endophthalmitis risk vs topical drops after cataract surgery, meta-analysis found.
This article discusses the evolution of the body of information about Demodex blepharitis over the years, from the convening of a consensus panel to the realization that a new drug provides rapid relief to the ocular surface.
Researchers from China and Singapore found that the macular microvasculature is altered as early as the pre-diabetic stage of the disease. The findings suggest that the status of the choriocapillaris can be used to monitor early metabolic disease.
Advertisement
Advertisement